Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD20 Monoclonal Antibody for GVHD Prophylaxis in Severe Aplastic Anemia
NCT05510505Phase 2Recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Dec 2021
- Primary completion
- Sep 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of rituximab in aplastic anemia and graft-versus-host disease (GVHD) (2 arms), sponsored by First Affiliated Hospital of Soochow University. Primary endpoint: Incidence of Graft-Versus-Host Disease at 2 years. Started Dec 2021; status: recruiting.
02
Drugs
rituximab
03
Conditions
aplastic anemiagraft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT05510505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05510505.